GlaxoSmithKline and partner Vir Biotechnology have started testing their experimental antibody on early-stage Covid-19 patients, entering the race to find a winner in a promising class of antiviral drugs to combat the pandemic, Reuters reported.
The British drugmaker said the long-acting single injection will be tested on recently diagnosed high-risk cases for its ability to prevent hospitalisation, typically a life-threatening disease stage.
GSK, which in April moved to invest $250 million in Vir and agreed to collaborate on the antibody, is behind some peers in developing the class.
